IP Library › Granted Patent US 11,458,210
Granted Patent B2
US 11,458,210 · App. 16/859,893 · Granted Oct 4, 2022

Compounds and compositions for targeting brain injuries and methods of use thereof

Inventors: Erkki Ruoslahti (La Jolla, CA); Aman Mann (La Jolla, CA); Pablo Scodeller (La Jolla, CA); Sazid Hussain (La Jolla, CA)
Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
A61K47/6929A61K9/0019A61K9/5115A61K47/62A61K47/6425A61K47/6923A61K48/005A61K48/0008A61P43/00C07K5/1013
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,458,210
App. No.
16/859,893
Granted
Oct 4, 2022
Kind
B2
Abstract

Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.

Claims (11)

1. A composition comprising a peptide linked or conjugated to a cargo composition, wherein the peptide consists of the amino acid sequence CAQK (SEQ ID NO:4).

2. The composition of claim 1 , wherein the peptide and the cargo composition are covalently coupled.

3. The composition of claim 1 , wherein the peptide selectively homes the cargo composition to a site of acute brain injury in a subject.

4. The composition of claim 1 , wherein the peptide selectively homes the cargo composition to a site of glial scar formation.

5. The composition of claim 1 , wherein the peptide specifically binds to one or more of versican, tenascin-R, and Hapln.

6. The composition of claim 1 , wherein the cargo composition comprises cargo molecules.

7. The composition of claim 6 , wherein the cargo molecules independently comprise a therapeutic agent, a labeling agent, a contrasting agent or an imaging agent.

8. The composition of claim 7 , wherein the therapeutic agent is a polypeptide or a nucleic acid molecule.

9. The composition of claim 1 , wherein the cargo composition further comprises a surface molecule.

10. The composition of claim 9 , wherein the surface molecule is selected from the group consisting of a nanoparticle, a nanoworm, an iron oxide nanoworm, an iron oxide nanoparticle, an albumin nanoparticle, a liposome, a micelle, a phospholipid, a polymer, a microparticle, a bead, a virus, a phage, a viral particle, a phage particle, a viral capsid, a phage capsid, a virus-like particle, or a fluorocarbon microbubble.

11. The composition of claim 1 , wherein the cargo composition comprises a functional nucleic acid encapsulated within a nanoparticle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: RUOSLAHTI, ERKKI; MANN, AMAN; SCODELLER, PABLO; HUSSAIN, SAZID
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 053341/0150 →
Continuity (3)
Division 15756947
Provisional Application 62213168 · Sep 2, 2015
Related Publication 20200368365A1 · Nov 26, 2020